A randomized, double-blind, placebo-controlled Phase 1 trial of TERN-101 for the treatment of non-alcoholic steatohepatitis (NASH)
Phase of Trial: Phase I
Latest Information Update: 13 Aug 2019
Price : $35 *
At a glance
- Drugs TERN-101 (Primary)
- Indications Non-alcoholic steatohepatitis
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Terns Pharmaceuticals
- 13 Aug 2019 According to a Terns Pharmaceuticals media release, the company looks forward to seeing further results from this study later in the year.
- 13 Jun 2019 According to a Terns pharmaceutical media release, the company is planning to evaluate data from this trial later in 2019.
- 13 Jun 2019 Status changed from planning to recruiting, as reported in a Terns pharmaceutical media release.